Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/μl in rural Uganda
Open Access
- 24 September 2014
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 28 (15) , 2241-2249
Abstract
Background: HIV antiretroviral therapy (ART) is being rapidly scaled up in sub-Saharan Africa, including recently patients with CD4+ T-cell counts above 350 cells/μl. However, concerns persist about adherence and virologic suppression among these asymptomatic, high CD4+ cell count individuals. Objective: To determine the virologic efficacy and safety of ART among asymptomatic HIV-positive Ugandan adults with high CD4+ cell counts above 350 cells/μl via a streamlined model of care. Design: Prospective nonrandomized clinical study (EARLI Study: clinicaltrials.gov NCT#01479634). Setting: Prototypic rural Ugandan HIV clinic. Patients/participants: Asymptomatic, ART-naive adults (aged >18 years, N = 197) with CD4+ at least 350 cells/μl, without pregnancy or WHO stage 3/4 illness. Interventions: ART included tenofovir/emtricitabine/efavirenz, with ritonavir/lopinavir substitution for efavirenz available. Streamlined ART model included nurse-driven visits with physician back-up, basic safety laboratory monitoring with HIV viral load, clinician telephone contact, and defaulter tracking. No incentives were provided. Outcomes: Undetectable viral load (≤400 copies/ml) at 24 and 48 weeks [intention to treat (ITT); missing = detectable), self-reported ART adherence, retention in care, and laboratory/clinical ART toxicities. Results: Of the 197 patients with CD4+ above 350 cells/μl, median CD4+ cell count was 569 cells/μl (interquartile range 451–716). Undetectable viral load was achieved in 189 of 197 (95.9%, ITT) and 189 of 195 (96.9%, ITT) of participants at weeks 24 and 48, respectively. Self-reported adherence was 98% and 192 of 197 (97%) of the patients were retained at week 48. Laboratory adverse events and hospitalizations were rare. Conclusions: We demonstrate high virologic suppression, retention, and safety among asymptomatic individuals with CD4+ above 350 cells/μl in a prototypic Ugandan clinic. Our results challenge current concerns that individuals with high CD4+ cell count lack motivation for ART, and may not achieve sustained virologic suppression.Keywords
This publication has 24 references indexed in Scilit:
- ‘If I am given antiretrovirals I will think I am nearing the grave’AIDS, 2014
- A Pharmacy-Only Refill Program at a Large HIV Clinic in UgandaJournal of the International Association of Providers of AIDS Care (JIAPAC), 2013
- Higher Baseline CD4 Cell Count Predicts Treatment Interruptions and Persistent Viremia in Patients Initiating ARVs in Rural UgandaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2013
- Toward an Understanding of Disengagement from HIV Treatment and Care in Sub-Saharan Africa: A Qualitative StudyPLOS Medicine, 2013
- Leveraging Rapid Community-Based HIV Testing Campaigns for Non-Communicable Diseases in Rural UgandaPLOS ONE, 2012
- Excellent Clinical Outcomes and High Retention in Care Among Adults in a Community-Based HIV Treatment Program in Rural RwandaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Antiretroviral therapy refusal among newly diagnosed HIV-infected adultsAIDS, 2011
- A Randomized Trial of Punctuated Antiretroviral Therapy in Ugandan HIV-Seropositive Adults With Pulmonary Tuberculosis and CD4+ T-Cell Counts of ≥350 cells/μLThe Journal of Infectious Diseases, 2011
- Client and Provider Perspectives of the Efficiency and Quality of Care in the Context of Rapid Scale-Up of Antiretroviral TherapyAIDS Patient Care and STDs, 2010
- Improvement of the patient flow in a large urban clinic with high HIV seroprevalence in Kampala, UgandaInternational Journal of STD & AIDS, 2009